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Will drug resistance against
dolutegravir in initial therapy ever
occur?
Mark A. Wainberg* and Ying-Shan Han
Lady Davis Institute for Medical Research, McGill University AIDS Centre, Jewish General Hospital, Montreal, QC, Canada
Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and
INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation
INSTIs, raltegravir, and elvitegravir, DTG shows a limited cross-resistance profile. More
interestingly, clinical resistance mutations to DTG in treatment-naive patents have not
been observed to this date. This review summarizes recent studies on resistance
mutations to DTG and on our understanding of the mechanisms of resistance to DTG
as well as future directions for research.
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Introduction
Antiretroviral therapy (ART) usually involves a combination of at least three diﬀerent antiretroviral
(ARV) drugs to maximally suppress HIV propagation and stop the progression of HIV disease.
ART has led to a huge decrease in HIV-related morbidity and mortality, particularly when it is
used in early stages of disease. Currently, 29 ARV drugs, belonging to six diﬀerent classes that act
at diﬀerent stages of the HIV life cycle, have been approved by the Food and Drug Administration
(FDA) of the U.S. for use in the clinic. However, HIV can develop resistance to evade the eﬀects of
treatment by almost all classes of ARV drugs.
Integrase strand transfer inhibitors (INSTIs), which block the integration of HIV viral DNA into
host chromosomal DNA, are the latest class of ARV drugs. So far, there are three approved INSTIs,
raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG). RAL and EVG, the ﬁrst generation
INSTIs, are highly eﬀective in treatment of patients with HIV. But HIV resistance to both RAL and
EVG can emerge relatively rapidly in tissue culture and can also arise in patients as a result of single
mutations or primary mutations that are in combination with a secondary mutation in integrase
(Geretti et al., 2012; Mesplede et al., 2013; Quashie et al., 2013b; Grobler and Hazuda, 2014). Cross
resistance to DTG between RAL and EVG has also been documented.
However, DTG, a second generation INSTI, has shown a superior barrier to resistance compared
to that seen with RAL or EVG. DTG is able to inhibit RAL- and EVG-resistant viruses either
completely or partially in vitro. Importantly DTG is the only anti-HIV drug that HIV has not
developed resistance mutations against when the drug is used in ﬁrst line therapy (Mesplede and
Wainberg, 2014). This review summarizes recent ﬁndings on resistance mutations to DTG and the
underlying mechanisms that may be responsible for the absence of resistance to DTG in ﬁrst line
therapy.
HIV Resistance to DTG
Raltegravir and EVG share similar resistance proﬁles in regard to mutations in the active site of
integrase. Furthermore, resistance to RAL and EVG can emerge rapidly both in vitro and in patients
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(Geretti et al., 2012). Resistance to RAL includes three major
mutational pathways involving positions Y143, Q148, and N155
in integrase. For EVG, major primary mutations include T66I,
E92Q, N155H, and Q148H/K/R. Extensive cross resistance
between RAL and EVG can occur through mutations at position
155 and 148. In comparison with the ﬁrst generation INSTIs RAL
and EVG, DTG has a higher resistance barrier (Wainberg et al.,
2013; Llibre et al., 2014; White et al., 2014), and also shows less
sensitive to the changes caused by mutations at N155 and Q148
(Abram et al., 2013; Quashie et al., 2013b; Table 1).
Some mutations that are potentially involved in integrase
resistance to DTG and that were selected in vitro and in vivo
include F121, S153, G118, E138, and R263 (Kobayashi et al.,
2011; Quashie et al., 2012). These mutations alone or in combi-
nation with accessory mutations did not abrogate susceptibility
to DTG, but did impair viral replicative ﬁtness to varying extent
(Table 2). The most common mutation identiﬁed in cell culture
selections with DTG was R263K and this substitution was shown
to confer low-level resistance to DTG (fold change, FC= 2.3-fold;
Quashie et al., 2012). R263K also impaired strand transfer activ-
ity and decreased viral replication capacity (RC). R263K has been
reported in several treatment-experienced, INSTI-naïve patients
(Cahn et al., 2013).
Usually a combination of primary mutation and secondary
mutations increase levels of drug resistance while restoring viral
replication ﬁtness. In cell culture selections in the presence of
DTG, R263K was often observed together with H51Y in subtype
B and recombinant A/G viruses. H51Y alone has no eﬀects on
resistance to DTG. However, the addition of H51Y to R263K
increases resistance to DTG to ∼eightfold in a HIV susceptibil-
ity assay using TZM-bl cells and dramatically decreases viral RC
by ∼90%; enzyme strand transfer activity is reduced by ∼80%
(Mesplede et al., 2013).
Similarly, M50I was identiﬁed as an accessory mutation in
association with R263K in cell cultures selected under DTG pres-
sure and has been also reported in a patient failing treatment
with RAL. The natural polymorphism M50I alone has no inﬂu-
ence on strand transfer activity and viral RC. Relative to M50I
alone, the combination of M50I and R263K increased resistance
to DTG to 5.6-fold, but did not restore viral RC (Wares et al.,
2014). Moreover, recent studies showed that the addition of
E138K to R263K modestly increased resistance to DTG in cell
culture (FC = 4.3) and slightly increased susceptibility to DTG
in cell-free strand-transfer assay from FC = 3 to FC = 4.4. The
combination of E138K and R263K decreased integrase strand-
transfer activity to about 60% compared to the WT enzyme and
failed to restore viral infectivity (∼twofold decrease) and RC
(Mesplede et al., 2014).
Another common mutation for resistance to DTG that was
selected in cell culture is G118R (Quashie et al., 2014). Viruses
containing R263K or G118R, alone or in combination with
secondary mutations, often severely impaired virus RC. This may
be the reason that primary resistance to DTG is so rare in clinical
studies performed to date.
The mutations at R263K, G118R, H51Y, and E138K in inte-
grase have been shown to confer low-level resistance to DTG.
A recent study tested the ability of viruses harboring DTG-
resistant mutations at either R263K or G118R and/or H51Y
TABLE 1 | Major resistance pathways to raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG).
Mutational pathways Fold resistance
RAL EVG DTG
Y143 pathway Y143C
Y143R
T97A/Y143C
T97A/Y143R
L74M/T97A/Y143G
L74M/T97A/E138A/Y143C
<10
<50
>100
>100
<50
<20
<2
<2
<2
<2
ND
ND
<2
<2
<2
<2
<2
<2
N155 pathway N155N
E92Q/N155H
L74M/N155H
<50
<100
<50
50
>100
<50
<2
<10
<2
Q148 pathway Q148H
Q148K
Q148R
E138K/Q148H
E138K/Q148K
E138K/Q148R
G140S/Q148H
G140S/Q148K
G140S/Q148R
E138A/G140S/Y143H/Q148H
<20
<100
<50
<10
>100
>100
>100
<10
>100
>100
<10
<100
<100
<20
>100
>100
>100
<100
>100
ND
<2
<2
<2
<2
<10
<10
<20
<2
<10
<50
R263K pathway R263K
R263K/H51Y
<1
3–5
3
3
4
4–6
G118R pathway G118R
G118R/H51Y
G118R/E138K
10–17
ND
4–20
>5
ND
4–5
>8
ND
8–13
ND, not detected. Quashie et al. (2013b, 2014).
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TABLE 2 | Effects of mutations in integrase on resistance to INSTIs, viral replication capacity (RC), and strand transfer activity.
Genotype Strain Phenotypic assay Susceptibility to INSTIs (Fold change) RC (FC) STA (FC) Reference
RAL EVG DTG
WT NL43 TZM-bl cells 1 1 1 1 1 Wares et al. (2014)
M50I 0.47 5.45 1.94 0.92 1.1
R263K 1.85 21.4 8.55 0.7 0.22
M50I/R263K 3.56 34.44 15.59 0.7 0.31
WT NL43 PhenoSense 1 1 1 1 1 Mesplede et al. (2013)
H51Y 1.11 2.06 1.25 0.89 1.07
R263K 1.21 3.28 1.95 0.7 0.45
H51Y/R263K 2.94 41.5 6.95 0.11 0.2
WT NL43 TZM-bl cells 1 1 1 1 1 Mesplede et al. (2014)
E138K 1 0.8 0.4 0.83 2.4
R263K 1.2 21.8 2.3 0.72 0.5
E138K/R263K 1 16 4.3 0.71 0.6
WT NL43 PM1 cells 1 1 1 1 1 Bar-Magen et al. (2010), Quashie et al. (2013a)
G118R 0.78 1 – 0.02 0.04
G118R/H51Y – – – – 0.06
G118R/E138K 2.33 2 – 0.13 0.08
RC, replication capacity; STA, strand transfer activity; WT, wild-type.
in the development of other mutations associated with resis-
tance to reverse transcriptase inhibitors such as lamivudine
(3TC) or nevirapine (NVP) in cell culture. As expected, wild-
type (WT) viruses developed M184V/I, typical mutations that
confer resistance to 3TC, in the presence of this drug as early
as 6 weeks. The virus with the H51Y mutation alone was not
impaired in ability to generate M184V/I mutation under 3TC
pressure. However, the virus harboring R263K was delayed in
ability to generate M184V/I mutation by 2 weeks. Similarly,
the V106A resistance mutation for NVP was detected in WT
virus in the presence of NVP at 6 weeks, while the virus carry-
ing R263K developed the V106A mutation between weeks 11
and 14, i.e., a delay of at least 5 weeks. The viruses contain-
ing a combination of H51Y/R263K developed the V106A resis-
tance mutation at week 11, also a delay of 5 weeks. The G118R
and H51Y/G118R containing viruses did not develop any rele-
vant resistance mutations to 3TC or NVP until week 25, when
Y181C that confers resistance to NVP was present. These results
clearly show that the R263K or G118R mutations, alone or
in combination with H51Y, can delay the emergence of muta-
tions that confers resistance to each of NVP and 3TC. These
delays might be most likely caused by the decreased viral RC
associated with the DTG-resistance mutations (Oliveira et al.,
2014).
In the development of HIV resistance to drugs, compen-
satory mutations in HIV often increase levels of drug resistance
while simultaneously restoring impaired viral ﬁtness to normal
level. Of note, no such additional compensatory mutations have
been identiﬁed for DTG, even in cell culture selection experi-
ments, for more than 4 years (Wainberg et al., 2013; Mesplede
and Wainberg, 2014). Interestingly, combinations of R263K with
primary resistance mutations for RAL and EVG at positions 143
and 148 resulted in vastly diminished enzymatic activity that
may be incompatible with viral survival, which helps to explain
why R263K has never been observed in the clinic together with
primary RAL or EVGmutations (Anstett et al., 2014).
So far, virological failure has not yet been reported in
treatment-naive individuals receiving DTG-containing regimens
in clinical practice (Mesplede and Wainberg, 2014). This may be
partially explained by the fact that the presence of mutations that
confer resistance to DTG can impair the ability of HIV to develop
further resistance against 3TC and NVP. Thus, we conclude that
a DTG-containing regimen may not lead to virological failure,
even if the R263K mutation is present. This hypothesis will need
to be veriﬁed by ultrasensitive sequencing of the integrase gene
from residual plasma viral RNA or the DNA of lymphocytes of
patients who have been successfully treated with DTG (Oliveira
et al., 2014).
Since no treatment-naïve patient treated with DTG has yet
developed resistance to this drug and since the R263K mutation
confers only low-level resistance in cell culture, it was postulated
that DTG may be useful in attempts to limit HIV persistence. To
investigate the impact of the R263Kmutation on HIV RC and the
ability of HIV viruses to establish or be reactivated from latency
and/or spread through cell-to-cell transmission, a series of
constructs containing EGFP were created by site-directed muta-
genesis, including pNL4-3-IRES-EGFP-INR263K, pNL4-3-IRES-
EGFP-INE138K, pNL4-3-IRES-EGFP-INE138K/R263K. The relevant
replication competent reporter viruses were produced and used
to study the eﬀects of R263K on HIV RC, the ability to estab-
lish latency and/or to spread through cell-to-cell transmission in
Jurkat cells. As expected, the R263K mutation caused diminished
RC and infection. However, the DTG-resistant viruses were still
eﬃciently transmitted via cell-to-cell contacts, and were as likely
to establish and be reactivated from latent infection as wild type
viruses (Bastarache et al., 2014).
The integrase baseline sequence can aﬀect each of these muta-
tions in regard to susceptibility to DTG. One study showed that
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DTG was eﬀective against RAL-resistant variants containing the
N155H, Y143C, N155H/Y143C, and G140S/Q148Hmutations in
diﬀerent cell types, including C8166, human primary monocyte
derived macrophages (MDMs), peripheral blood mononuclear
cells (PBMCs) (Pollicita et al., 2014). Similarly, it has been shown
that DTG is eﬀective against patient-derived RAL-resistant vari-
ants containing Y143 or N155 mutations in both macrophages
and CD4+ T cells. Only Q148H/R-bearing variants showed a
reduced level of susceptibility (FC 5.5–19; Canducci et al., 2013).
In one case, a RAL-resistant patient harboring N155H was
switched to a DTG-containing regimen for about 10 months. The
acquisition of mutations at T97A and E138K in integrase led to
37-fold resistance to DTG. After the use of DTG for 10 more
months, the sequential acquisition of mutations at A49P, L68FL,
and L234V led to further resistance to DTG (FC 63-fold). Of
these, A49P and L234V are novel mutational pathways leading
to emergent DTG resistance while on salvage therapy with the
N155H mutation (Hardy et al., 2015).
It was also observed that the sequential acquisition of DTG
resistance mutations was associated with signiﬁcant deﬁcits in
viral replicative capacity (41%) relative to levels observed (101–
187%) prior to treatment with DTG (Hardy et al., 2015). In
another case, a patient harboring a virus with high level resistance
to all reverse transcriptase and protease inhibitors and S119R,
N155H, and E157Q mutations in integrase after RAL failure was
treated with DTG and RAL was removed. One month later, viral
load was undetectable and after 8 months, two new mutations
T97A and S147G in integrase were detected (Carganico et al.,
2014). The G118Rmutation was detected in a RAL-failing patient
harboring a subtype CRF02_AG virus and the F121Y mutation
alongside other mutations was detected in a RAL-failing subtype
B patient. Phenotypic analysis in cell culture showed that the
G118R and F121Y mutations conferred broad cross-resistance to
all three currently used INSTIs, with higher resistance observed
with clinical isolates than with a NL43 backbone (Malet et al.,
2014). These results suggest that DTG should be used with
caution in INSTI salvage therapy for RAL failures. However,
several INSTI-experienced patients with extensive resistance who
were treated with DTG demonstrated excellent virological and
immunological responses (Hofstra et al., 2014).
Insights into Mechanisms of HIV
Resistance to DTG
Recently, considerable progress has been made in studies on
mechanisms of HIV resistance to DTG. It is widely accepted
that the higher genetic barrier to resistance of DTG is due
to its slow dissociation rate from integrase-DNA complexes in
comparison to RAL and EVG (Hightower et al., 2011; Geretti
et al., 2012; Wainberg et al., 2013). Studies on binding modes of
all INSTIs to prototype foamy virus (PFV) intasomes, a surro-
gate for the HIV-1 intasome, have shown that an extended
linker of DTG allows its diﬂuorophenyl group to enter farther
into the pocket within the integrase active site than other
INSTIs and that DTG has the ability to adjust its structure
and conformation in response to structural changes within the
active sites of RAL- and EVG-resistant integrases, compared
to RAL and EVG (Figure 1; Hare et al., 2011; Quashie et al.,
2013b). Biochemical studies have provided further insight into
the mechanism of resistance to DTG. It has been shown that the
R263K mutation in integrase results in decreases in 3′-processing
and strand transfer activities. Homology modeling of intasomes
and strand transfer complexes from WT and R263K-containing
FIGURE 1 | Chemical structures of (A) raltegravir (RAL), (B) elvitegravir (EVG), and (C) dolutegravir (DTG) and their binding modes to the prototype
foamy virus (PFV) integrase active site (Quashie et al., 2013b).
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integrases reveals altered interactions in integrase-DNA. In addi-
tion, an integrase-DNA binding assay showed that the R263K
mutation decreased integrase-viral DNA binding (Quashie et al.,
2012). Similarly, biochemical studies have shown that the G118R
mutation in integrase greatly decreases strand transfer activ-
ity but does not aﬀect 3′-processing activity (Quashie et al.,
2013a).
The low levels of resistance to DTG conferred by mutations
in integrase correlate with decrease in strand transfer activity
and viral RC (Table 2). A recent study on homology modeling
of constructed tetrameric HIV-1 intasome revealed the molec-
ular mechanism of cross-resistance conferred by E138K/Q148K
to RAL, EVG, and DTG. Using molecular dynamics simula-
tion and residue interaction network (RIN) analysis, the work
showed that P145 in the 140S loop (G140–G149) of the inta-
some has strong hydrophobic interactions with INSTIs and is
involved in a conformational rearrangement at the active site
of the HIV-1 intasome. Furthermore, a systematic RIN analysis
demonstrated that communications between the residues in the
resistance mutant are increased compared with those of the WT
HIV-1 intasome. In addition, the chelating ability of the oxygen
atoms in INSTIs (e.g., RAL and EVG) to Mg2+ in the active
site of the resistant integrase was reduced due to conformational
change and is most likely responsible for the cross-resistance
(Xue et al., 2013). More recently, a computational analysis of
G118R and F121Y mutation conferring high-level resistance to
RAL, EVG, and DTG, showed that these substitutions were asso-
ciated with reduced binding aﬃnities to each of the INSTIs and
with a decreased number of hydrogen bonds compared with
the WT complexes (Malet et al., 2014). These ﬁndings provide
valuable information on the mechanism of resistance to INSTIs
and will be useful for structure-based design of novel INSTIs
that may possess better resistance proﬁle than currently available
drugs.
Perspectives
Currently, patients treated with DTG-containing regimens
achieve high rate of eﬃcient responsiveness up to 90%, though
some patients have failed therapy. Interestingly, no resistance
mutations to DTG in treatment-naive patients have yet been
identiﬁed. Moreover, selection of resistance with DTG in cell
culture has yielded only two mutations that confer low level resis-
tance to this drug, in association with a decrease in viral RC. So
far, no secondary compensatory mutations that might augment
resistance and restore viral RC have been observed in selec-
tion experiments in cell culture over more than 4 years. These
results may be explained by the fact that viruses containing DTG-
resistance mutations are relatively replication impaired and may
be unlikely to eﬃciently replicate in patients. If this is true, then
the development of low-level resistance to DTG in ﬁrst-line ther-
apy might not have adverse clinical consequences and DTG could
be used in Treatment as Prevention (TasP) protocols to reduce
viral load on a population level, which will eventually result in
diminished rates of HIV transmission (Mesplede et al., 2013;
Wainberg et al., 2013).
In addition, it is conceivable that DTG could be employed as
monotherapy in treatment-naive patients. In such a study, resis-
tance mutations to DTG in both the RNA of patient plasma
samples and the DNA of patient PBMCs would need to be inten-
sively monitored by ultrasensitive sequencing methods. If the
results are similar to those observed in the phase III clinical trials,
i.e., an absence of resistance to DTG, this would help to vali-
date the hypothesis outlined above. Could a number of cycles
of DTG monotherapy conceivably convert all the HIV, even that
in latent reservoirs, into replication-impaired forms? Perhaps
such an approach could lead to a functional cure of HIV disease
if all residual viruses were signiﬁcantly impaired in viral repli-
cation and if further compensatory mutations were unable to
develop. This concept could ﬁrst be studied in animal models
such as rhesus macaques that are infected by simian immunod-
eﬁciency virus (SIV) or humanized mice that are infected by HIV
(Wainberg et al., 2013).
Conclusion and Future Directions
Although INSTIs are highly potent drugs, HIV may still be able
to develop mutations that confer resistance against all currently
available ARVs. Thus, further characterization of the resistance
proﬁle of DTG, both in vitro and in the clinic, is important. More
sensitive assays are important, such as next-generation sequenc-
ing for the detection of low-level viremia and minority resistance
variants. Non-human primate models are important tools with
which to study issues of drug resistance as well as the persis-
tence and transmission of drug-resistant viruses (Hassounah
et al., 2014; Wares et al., 2015). Moreover, the development
of new classes of anti-HIV drugs with high resistance barriers
that have no cross-resistance with current drug classes is still
needed (White et al., 2014). Recently, it has been reported that
a compound similar to DTG, termed GSK1265744, can act as an
INSTI on a once-daily basis and that this drug possesses a distinct
resistance proﬁle compared with the earlier INSTIs, RAL, and
EVG (Yoshinaga et al., 2015). This provides hope for the future
of HIV prevention and treatment.
Key Concepts
Antiretroviral therapy: a regimen that consists of a combination
of at least three antiretroviral drugs to maximally suppress HIV
replication and stop the progression of HIV disease.
HIV drug resistance: the presence of HIV mutations that
reduce drug susceptibility compared with WT viruses.
Integrase strand transfer inhibitor: compounds that block
the strand transfer reaction of HIV integrase to prevent HIV
replication.
Viral ﬁtness: the ability of a virus to reproduce itself in host
cells.
HIV RC: a measurement of the virus’s ﬁtness.
Virologic failure: the inability to achieve or maintain suppres-
sion of viral replication to level less than 50 copies viral RNA/ml
of plasma.
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